The combination of the blood based tumor biomarkers cytokeratin 19 fragments (CYFRA 21-1) and carcinoembryonic antigen (CEA) as a potential predictor of benefit from adjuvant chemotherapy in early stage squamous cell carcinoma of the lung (SCC)

• Verfasst von: Muley, Thomas [VerfasserIn]
• Verfasst von: Warth, Arne [VerfasserIn]
• Verfasst von: Schneider, Marc [VerfasserIn]
• Verfasst von: Dienemann, Hendrik [VerfasserIn]
• Verfasst von: Meister, Michael [VerfasserIn]
• Verfasst von: Herth, Felix [VerfasserIn]
• Titel: The combination of the blood based tumor biomarkers cytokeratin 19 fragments (CYFRA 21-1) and carcinoembryonic antigen (CEA) as a potential predictor of benefit from adjuvant chemotherapy in early stage squamous cell carcinoma of the lung (SCC)
• Verf.angabe: Thomas Muley, Vinzent Rolny, Ying He, Birgit Wehnl, Achim Escherich, Arne Warth, Christa Stolp, Marc A. Schneider, Hendrik Dienemann, Michael Meister, Felix J. Herth, Farshid Dayyani
• E-Jahr: 2018
• Jahr: 17 March 2018
• Umfang: 8 S.
• Teil: volume:120
• Teil: year:2018
• Teil: pages:46-53
• Teil: extent:8
• Fussnoten: Gesehen am 27.05.2019
• Titel Quelle: Enthalten in: Lung cancer
• Ort Quelle: Amsterdam [u.a.] : Elsevier, 1985
• Jahr Quelle: 2018
• Band/Heft Quelle: 120(2018), Seite 46-53
• ISSN Quelle: 1872-8332
• DOI: doi:10.1016/j.lungcan.2018.03.015
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: Adjuvant chemotherapy
• Sach-SW: CEA
• Sach-SW: CYFRA 21-1
• Sach-SW: NSCLC
• Sach-SW: Prognosis
• Sach-SW: Squamous cell carcinoma
• K10plus-PPN: 1666350214

Abstract

Objectives - To determine whether the tumor biomarkers cytokeratin 19 fragment (CYFRA 21-1) and carcinoembryonic antigen (CEA), which are prognostic in early-stage non-small cell lung cancer (NSCLC), can predict which patients benefit from adjuvant chemotherapy (CTx). - Materials and methods - Serum samples were collected preoperatively from patients with NSCLC who underwent resection. Samples were retrospectively analyzed for CYFRA 21-1 and CEA via electrochemiluminescence immunoassay. Recurrence-free survival (RFS) was compared for patients who received adjuvant CTx versus surgery alone, stratified based on the following prognostic classifications: (1) tumor stage (pT1‐2/N0 [stage I] or pT3/N0 or pT1‐2/N1 [stage II]), (2) biomarker-based risk score, (3) clinical characteristics. Absolute 2-year RFS rates were calculated via Kaplan-Meier estimations; statistical significance level: 0.05. - Results - 227 patients were included (stage I: 69%; male: 67%; median age 65 years); 70 received adjuvant CTx. Median duration of sample collection was 58.8 months. All high-risk patients (by all three prognostic classifications) who received adjuvant CTx had a longer RFS versus those who received surgery alone. In patients with squamous cell carcinoma (SCC) classified as high risk by all three prognostic classifications, there was a benefit from adjuvant CTx versus surgery alone (tumor stage hazard ratio [HR] 4.9, p=0.004; biomarker levels HR 9.4, p=0.002; clinical characteristics HR 9.0, p=0.003). None of the prognostic classifications were able to predict a benefit from adjuvant CTx in patients with adenocarcinoma. - Conclusion - Baseline CYFRA 21-1 and CEA levels may provide further information to help clinicians decide which patients with SCC should receive adjuvant CTx. Further evaluation of these biomarkers is warranted.